Literature DB >> 7289015

Management of asymptomatic hyperuricemia.

W B Duffy, H O Senekjian, T F Knight, E J Weinman.   

Abstract

Although the incidence of gout, renal stones, or both is increased in patients with hyperuricemia, there is no evidence that long-term therapy offers any substantial long-term benefits. Recent data also suggest that no clear relationship exists between hyperuricemia and the development of interstitial nephritis (so-called urate nephropathy). Finally, the relationship between elevations in the serum concentration of uric acid and the risk of developing cardiovascular disease remains undefined. It is recommended that, in a patient with asymptomatic hyperuricemia, a conservative approach be taken and hypouricemic therapy not be instituted as a matter of routine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7289015

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis.

Authors:  J Auböck; P Fritsch
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-29

2.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.

Authors:  Mehmet Kanbay; Bulent Huddam; Alper Azak; Yalcin Solak; Gulay Kocak Kadioglu; Ismail Kirbas; Murat Duranay; Adrian Covic; Richard J Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

Review 3.  Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society?

Authors:  Richard J Johnson; Yuri Y Sautin; William J Oliver; Carlos Roncal; Wei Mu; L Gabriela Sanchez-Lozada; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Steven A Benner
Journal:  J Comp Physiol B       Date:  2008-07-23       Impact factor: 2.200

Review 4.  The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.

Authors:  Yuka Sato; Daniel I Feig; Austin G Stack; Duk-Hee Kang; Miguel A Lanaspa; A Ahsan Ejaz; L Gabriela Sánchez-Lozada; Masanari Kuwabara; Claudio Borghi; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2019-07-11       Impact factor: 28.314

5.  Serum uric acid and target organ damage in essential hypertension.

Authors:  Sandra N Ofori; Osaretin J Odia
Journal:  Vasc Health Risk Manag       Date:  2014-05-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.